Intla!_老虎社区_美港股上老虎

SKYK
2021-06-27

Intla!

BRIEF-Intellia And Regeneron Announce Clinical Data For NTLA-2001<blockquote>BRIEF-Intellia 和 Regeneron 公布 NTLA-2001 临床数据</blockquote>

June 26 (Reuters) - Regeneron Pharmaceuticals Inc : * INTELLIA AND REGENERON ANNOUNCE LANDMARK C

BRIEF-Intellia And Regeneron Announce Clinical Data For NTLA-2001<blockquote>BRIEF-Intellia 和 Regeneron 公布 NTLA-2001 临床数据</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":124694513,"tweetId":"124694513","gmtCreate":1624761212632,"gmtModify":1633948968462,"author":{"id":3582026252026796,"idStr":"3582026252026796","authorId":3582026252026796,"authorIdStr":"3582026252026796","name":"SKYK","avatar":"https://static.tigerbbs.com/28c366259085ac1b7fe8b23c76611209","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Intla!</p></body></html>","htmlText":"<html><head></head><body><p>Intla!</p></body></html>","text":"Intla!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/124694513","repostId":2146009296,"repostType":2,"repost":{"id":"2146009296","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624720686,"share":"https://www.laohunote.com/m/news/2146009296?lang=zh_CN&edition=full","pubTime":"2021-06-26 23:18","market":"us","language":"en","title":"BRIEF-Intellia And Regeneron Announce Clinical Data For NTLA-2001<blockquote>BRIEF-Intellia 和 Regeneron 公布 NTLA-2001 临床数据</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2146009296","media":"Reuters","summary":"June 26 (Reuters) - Regeneron Pharmaceuticals Inc   :   * INTELLIA AND REGENERON ANNOUNCE LANDMARK C","content":"<p><html><body>June 26 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc   :</p><p><blockquote><html><body>6月26日（路透社）-<a href=\"https://laohu8.com/S/REGN\">再生元制药</a>公司：</body></html></blockquote></p><p>   * INTELLIA AND REGENERON ANNOUNCE LANDMARK CLINICAL DATA SHOWING DEEP REDUCTION IN DISEASE-CAUSING PROTEIN AFTER SINGLE INFUSION OF NTLA-2001, AN INVESTIGATIONAL CRISPR THERAPY FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS</p><p><blockquote>* INTELLIA 和 REGENERON 公布具有里程碑意义的临床数据，显示单次输注 NTLA-2001（一种治疗甲状腺素转运蛋白 (ATTR) 淀粉样变性的研究性 CRISPR 疗法）后，致病蛋白大幅减少</blockquote></p><p>   * REGENERON PHARMACEUTICALS - INTERIM READOUT IN ONGOING PHASE 1 TRIAL FINDS SINGLE 0.3 MG/KG DOSE OF NTLA-2001 LED TO 87% MEAN REDUCTION IN SERUM TTR</p><p><blockquote>*再生元制药-正在进行的1期试验的中期读数发现，单次0.3 MG/KG剂量的NTLA-2001导致血清TTR平均降低87%</blockquote></p><p>   * NO SERIOUS ADVERSE EVENTS OBSERVED IN FIRST SIX PATIENTS BY DAY 28</p><p><blockquote>*到第28天，前6例患者未观察到严重不良事件</blockquote></p><p>Source text for Eikon:    Further company coverage:   </p><p><blockquote>Eikon 的源文本：进一步的公司报道：</blockquote></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p><p><blockquote>((Reuters.Briefs@thomsonreuters.com;))</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Intellia And Regeneron Announce Clinical Data For NTLA-2001<blockquote>BRIEF-Intellia 和 Regeneron 公布 NTLA-2001 临床数据</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Intellia And Regeneron Announce Clinical Data For NTLA-2001<blockquote>BRIEF-Intellia 和 Regeneron 公布 NTLA-2001 临床数据</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2021-06-26 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>June 26 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc   :</p><p><blockquote><html><body>6月26日（路透社）-<a href=\"https://laohu8.com/S/REGN\">再生元制药</a>公司：</body></html></blockquote></p><p>   * INTELLIA AND REGENERON ANNOUNCE LANDMARK CLINICAL DATA SHOWING DEEP REDUCTION IN DISEASE-CAUSING PROTEIN AFTER SINGLE INFUSION OF NTLA-2001, AN INVESTIGATIONAL CRISPR THERAPY FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS</p><p><blockquote>* INTELLIA 和 REGENERON 公布具有里程碑意义的临床数据，显示单次输注 NTLA-2001（一种治疗甲状腺素转运蛋白 (ATTR) 淀粉样变性的研究性 CRISPR 疗法）后，致病蛋白大幅减少</blockquote></p><p>   * REGENERON PHARMACEUTICALS - INTERIM READOUT IN ONGOING PHASE 1 TRIAL FINDS SINGLE 0.3 MG/KG DOSE OF NTLA-2001 LED TO 87% MEAN REDUCTION IN SERUM TTR</p><p><blockquote>*再生元制药-正在进行的1期试验的中期读数发现，单次0.3 MG/KG剂量的NTLA-2001导致血清TTR平均降低87%</blockquote></p><p>   * NO SERIOUS ADVERSE EVENTS OBSERVED IN FIRST SIX PATIENTS BY DAY 28</p><p><blockquote>*到第28天，前6例患者未观察到严重不良事件</blockquote></p><p>Source text for Eikon:    Further company coverage:   </p><p><blockquote>Eikon 的源文本：进一步的公司报道：</blockquote></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p><p><blockquote>((Reuters.Briefs@thomsonreuters.com;))</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NTLA":"Intellia Therapeutics Inc","REGN":"再生元制药公司"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146009296","content_text":"June 26 (Reuters) - Regeneron Pharmaceuticals Inc   :   * INTELLIA AND REGENERON ANNOUNCE LANDMARK CLINICAL DATA SHOWING DEEP REDUCTION IN DISEASE-CAUSING PROTEIN AFTER SINGLE INFUSION OF NTLA-2001, AN INVESTIGATIONAL CRISPR THERAPY FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS   * REGENERON PHARMACEUTICALS - INTERIM READOUT IN ONGOING PHASE 1 TRIAL FINDS SINGLE 0.3 MG/KG DOSE OF NTLA-2001 LED TO 87% MEAN REDUCTION IN SERUM TTR   * NO SERIOUS ADVERSE EVENTS OBSERVED IN FIRST SIX PATIENTS BY DAY 28Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"NTLA":0.9,"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2070,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}